INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number
Filing Date
First Named Inventor

(Not for submission under 37 CFR 1.99)

 Application Number
 10624389

 Filing Date
 2005.07.22

 First Named Inventor
 Mark C. Estels

 At Unit
 3763

 Examiner Name
 MetBlew F. DeSartio

 Altomory Docket Number
 F09202/US

U.S.PATENTS Remove						
Examiner Cite Patent Number Kind Code ¹		Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5999849		1999-12-07	Gord et al.	
	2	6009339		1999-12-28	Bentsen et al.	
	3	6032119		2000-02-29	Brown et al.	
	4	6043437		2000-03-28	Schulman et al.	
	5	6067474		2000-05-23	Schulman et al.	
	6	6081736		2000-06-27	Colvin et al.	
	7	6083710		2000-07-04	Heller et al.	
	8	6088608		2000-07-11	Schulman et al.	

9	6101478	2000-08-08	Brown	
10	6103033	2000-08-15	Say et al.	
11	6119028	2000-09-12	Schulman et al.	
12	6120676	2000-09-19	Heller et al.	
13	6121009	2000-09-19	Heller et al.	
14	6134461	2000-10-17	Say et al.	
15	6135949	2000-10-24	Russo et al.	
16	6142008	2000-11-07	Cole et al.	
17	6143164	2000-11-07	Heller et al.	
18	6162611	2000-12-19	Heller et al.	
19	6171276	2001-01-09	Lippe et al.	

	Application Number		10624389	
	Filing Date		2003-07-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mark		C. Estes	
(Not for submission under 37 CFR 1.99)	Art Unit		3763	
(Not for Sabilission ander or or it issay	Examiner Name Matth		hew F. DeSanto	
	Attorney Docket Number		PF01022US	

20	6175752	2001-01-16	Say et al.	
21	6246992	2001-06-12	Brown	
22	6248067	2001-06-19	Causey et al.	
23	6250309	2001-06-26	Krichen et al.	
24	6254586	2001-07-03	Mann et al.	
25	6259937	2001-07-10	Schulman et al.	
26	6269340	2001-07-31	Ford et al.	
27	6270478	2001-08-07	Mem.o slashed.e	
28	6270481	2001-08-07	Mason et al.	
29	6295506	2001-09-25	Heinonen et al.	
30	6329161	2002-12-11	Heller et al.	

	Application Number		10624389	
	Filing Date		2003-07-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mark		C. Estes	
(Not for submission under 37 CFR 1.99)	Art Unit		3763	
(Not for Submission under or or it issue	Examiner Name Matth		hew F. DeSanto	
	Attorney Docket Numb	er	PF01022US	

31	6355018	2002-03-12	Vasko	
32	6461331	2002-10-08	Van Antwerp	
33	6472122	2001-10-29	Schulman et al.	
34	6484046	2002-11-19	Say et al.	
35	6503381	2003-01-07	Gotoh et al.	
36	6514718	2003-02-04	Holler et al.	
37	6551276	2003-04-22	Mann et al.	
38	6554798	2003-04-29	Mann et al.	
39	6556963	2003-04-29	Tetzlaff	
40	6558320	2003-05-06	Causey, III et al.	
41	6560741	2003-05-06	Heller et al.	

	42	6565509	2003-05-20	Say et al.	
	43	6579690	2003-06-17	Bonnecaze et al.	
	44	6591125	2003-07-08	Buse et al.	
	45	6592745	2003-07-15	Feldman et al.	
	46	6605200	2003-08-12	Mao et al.	
	47	6605201	2003-08-12	Mao et al.	
	48	6607658	2003-08-19	Heller et al.	
	49	6616819	2003-09-09	Liamos et al.	
	50	6618934	2003-09-16	Feldman et al.	
If you wisl	h to a	dd additional U.S. Pater		ease click the Add button.	Add Remove
Examiner Initial*	Cite No	Publication Number	Publication	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10624389		
Filing Date		2003-07-22		
First Named Inventor	Mark C. Estes			
Art Unit		3763		
Examiner Name	Matth	ew F. DeSanto		
Attorney Docket Number		PF01022US		

Date Considered

	1								
If you wis	h to a	dd additional U.S. Publ	ished Application	citatio	n information p	please click the Add butte	on. Add		
			FOREIG	GN PAT	TENT DOCUM	IENTS	Remove		
Examiner Initial*	Cite No	te Foreign Document Country Kind Publication Name of Patentee or Numbers Code2 i Code4 Date Procument Patentee or Applicant of cited Passage					Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS	
	1								
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Cite Initials* linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.							T5		
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								

Take Not Code of 1897/0 Pend Documents of your USETO.000 on METS 9510.6. To find often believed the document, by the her-befor code (NOC) Second of 73.3. "To hyperine plant of controls, the included of the year of the region of the Deposer must provide the serial number of the plant of beautiful observed by the approvide symbols are advanted on the document under NOTO Second of 17.6 if you have of the plant observed the plant of t

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10624389		
Filing Date		2003-07-22		
First Named Inventor	Mark C. Estes			
Art Unit		3763		
Examiner Name	Matth	ew F. DeSanto		
Attorney Docket Number		PF01022US		

CERTIFICATION STATEMENT

Please see 3	7 CFR	1.97 and	1.98 to make th	e appropriate selection(s):
--------------	-------	----------	-----------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Vivian S. Shin/	Date (YYYY-MM-DD)	2007-06-12
Name/Print	Vivian S. Shin	Registration Number	43 919

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral purpuses for which the information is used by the U.S. Patient and Trademan Colline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested region of the patient of the patient application of the patient application of the patient activities, which may result in farministion of proceedings or 4 anahoroment of the application of the patients of the pa

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be discbesed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.